Edition:
United Kingdom

Achillion Pharmaceuticals Inc (ACHN.OQ)

ACHN.OQ on NASDAQ Stock Exchange Global Select Market

2.84USD
22 Jun 2018
Change (% chg)

$0.01 (+0.35%)
Prev Close
$2.83
Open
$2.85
Day's High
$2.89
Day's Low
$2.67
Volume
718,220
Avg. Vol
339,868
52-wk High
$5.66
52-wk Low
$2.60

Chart for

About

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the... (more)

Overall

Beta: 1.68
Market Cap(Mil.): $650.99
Shares Outstanding(Mil.): 136.76
Dividend: --
Yield (%): --

Financials

  ACHN.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -0.50 -- --
ROI: -17.34 2.00 14.38
ROE: -17.36 3.49 16.08

BRIEF-Achillion Pharma Says Truitt Gets Annualized Base Salary Of $560,000

* ACHILLION PHARMACEUTICALS SAYS JOSEPH TRUITT RECEIVES ANNUALIZED BASE SALARY OF $560,000, IN CONNECTION WITH APPOINTMENT AS CEO - SEC FILING

02 May 2018

BRIEF-Achillion Reports Q1 Loss Per Share $0.15

* ACHILLION REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND MANAGEMENT TRANSITION

02 May 2018

BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy

* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY

26 Feb 2018

BRIEF-Achillion Forecasts 2018 Loss Of $0.55-$0.58 Per Share

* ACHILLION ANNOUNCES RESTRUCTURING TO ADVANCE CORPORATE STRATEGY; ANNOUNCES 2017 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

22 Feb 2018

Competitors

Earnings vs. Estimates